About Creo Medical Group (LON:CREO)
Creo Medical Limited develops and sells instruments for surgical endoscopy in the United Kingdom. The company is developing instruments for endoscopy through a combination of bipolar radiofrequency and microwave energy in a single platform for tissue dissection, resection, ablation, and coagulation. It offers Speedboat RS2 instrument for endoscopic submucosal dissection. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was founded in 2003 and is based in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolLON:CREO
CUSIPN/A
Phone+44-1291-606005
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-43.07%
Return on Assets-38.22%
Miscellaneous
EmployeesN/A
Outstanding Shares80,710,000
Creo Medical Group (LON:CREO) Frequently Asked Questions
What is Creo Medical Group's stock symbol?
Creo Medical Group trades on the London Stock Exchange (LON) under the ticker symbol "CREO."
How were Creo Medical Group's earnings last quarter?
Who are Creo Medical Group's key executives?
Creo Medical Group's management team includes the folowing people:
- Mr. Craig Jonathan Gulliford, CEO & Director (Age 47)
- Prof. Christopher Paul Hancock, Founder, CTO & Director (Age 50)
- Mr. Steve Morris, Co-Founder and Chief Operating Officer
- Mr. Richard John Rees ACA, CFO, Company Sec. & Director (Age 41)
- Mr. Phil Hales, Sales & Marketing Director
Has Creo Medical Group been receiving favorable news coverage?
News headlines about CREO stock have been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Creo Medical Group earned a daily sentiment score of 0.20 on Accern's scale. They also assigned media headlines about the company an impact score of 44.92 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Creo Medical Group?
Shares of CREO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Creo Medical Group's stock price today?
One share of CREO stock can currently be purchased for approximately GBX 122.50.
How big of a company is Creo Medical Group?
Creo Medical Group has a market capitalization of £91.76 million.
How can I contact Creo Medical Group?
The company can be reached via phone at +44-1291-606005.
MarketBeat Community Rating for Creo Medical Group (CREO)
MarketBeat's community ratings are surveys of what our community members think about Creo Medical Group and other stocks. Vote "Outperform" if you believe CREO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CREO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Creo Medical Group (LON:CREO) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
(Data available from 4/25/2016 forward)
Creo Medical Group (LON:CREO) Earnings History and Estimates Chart
Creo Medical Group (LON CREO) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/20/2018 | S1 2018 | | GBX (5) | | | View | N/A |  |
(Earnings results data provided by Zacks Investment Research)
Creo Medical Group (LON:CREO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Creo Medical Group (LON CREO) Insider Trading and Institutional Ownership History
Creo Medical Group (LON CREO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/9/2018 | Steve Morris | Insider | Buy | 115,325 | GBX 68 | £78,421 | | |
| 12/21/2017 | Christopher Paul Hancock | Insider | Buy | 36,664 | GBX 69 | £25,298.16 | | |
| 4/4/2017 | Christopher Paul Hancock | Insider | Buy | 106,038 | GBX 82 | £86,951.16 | | |
(Data available from 1/1/2013 forward)
Creo Medical Group (LON CREO) News Headlines
| Source: |
|
Creo Medical Group (LON:CREO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Creo Medical Group (LON CREO) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
